VivoSim Unveils 96% Accurate AI Diarrhea Prediction Using 3D Intestinal Models
VivoSim’s VitroSense AI tool uses data from its NAMkind ileum and colon models to predict drug-induced diarrhea with 96% accuracy. The platform’s 3D human tissue assays support oral or IV dosing and are now offered globally to screen oncology antibody-drug conjugates for intestinal toxicity.
1. AI-Driven Diarrhea Prediction Tool
VivoSim’s VitroSense toolkit integrates machine-learning analytics with high-quality NAMkind ileum and colon assay data to predict compound-induced diarrhea. Trained on dozens of drug candidates, the AI model delivered a 96% accuracy rate in identifying disruptions to intestinal epithelial integrity linked to diarrhea risk.
2. Integration with 3D Human Tissue Models
The NAMkind platform replicates multilayered human intestinal tissues, enabling both oral and intravenous dosing simulations. Assays measure epithelial barrier function, permeability endpoints and differential effects of antibodies versus payloads to generate comprehensive toxicity profiles.
3. Impact on Oncology Drug Development
With many cancer therapies limited by gastrointestinal side effects, VivoSim’s AI-driven screening allows clients to flag potential intestinal toxicities in antibody-drug conjugate candidates early, reducing reliance on animal testing and expediting clinical progression.
4. Global Service Expansion
VivoSim now offers NAMkind intestinal and liver toxicology services in the US, Europe, Korea and China, with ongoing capacity scaling to meet growing demand for human-relevant preclinical safety data.